# Vassiliki A. Papadimitrakopoulou

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/vassiliki-a-papadimitrakopoulou/

## Facts

| Field | Value |
| --- | --- |
| Citations | 27,608 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 82 |
| i10-index | 186 |
| Last Known Institution | Pfizer (United States) |
| OpenAlex ID | https://openalex.org/A5008790176 |
| ORCID iD | https://orcid.org/0000-0003-3172-1399 |
| Works | 530 |

## Researcher papers

- [Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer](https://scholariq.org/papers/osimertinib-or-platinum-pemetrexed-in-i-egfr-i-t790m-positive-lung-cancer/)
- [<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung Adenocarcinoma](https://scholariq.org/papers/i-stk11-lkb1-i-mutations-and-pd-1-inhibitor-resistance-in-i-kras-i-mutant-lung/)
- [Co-occurring Genomic Alterations Define Major Subsets of <i>KRAS</i> -Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities](https://scholariq.org/papers/co-occurring-genomic-alterations-define-major-subsets-of-i-kras-i-mutant-lung/)
- [The BATTLE Trial: Personalizing Therapy for Lung Cancer](https://scholariq.org/papers/the-battle-trial-personalizing-therapy-for-lung-cancer/)
- [Rociletinib in <i>EGFR</i>-Mutated Non–Small-Cell Lung Cancer](https://scholariq.org/papers/rociletinib-in-i-egfr-i-mutated-non-small-cell-lung-cancer/)
- [Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome](https://scholariq.org/papers/effect-of-kras-oncogene-substitutions-on-protein-behavior-implications-for/)
- [CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade](https://scholariq.org/papers/cd38-mediated-immunosuppression-as-a-mechanism-of-tumor-cell-escape-from-pd-1-pd/)
- [Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in <i>EGFR</i> -Mutant NSCLC](https://scholariq.org/papers/landscape-of-egfr-dependent-and-independent-resistance-mechanisms-to-osimertinib/)
- [Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis](https://scholariq.org/papers/osimertinib-versus-platinum-pemetrexed-for-patients-with-egfr-t790m-advanced/)
- [Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer](https://scholariq.org/papers/circulating-tumor-dna-analysis-depicts-subclonal-architecture-and-genomic/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [RNA modifications and cancer](https://scholariq.org/topics/rna-modifications-and-cancer/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)

## Researcher university

- [Pfizer (United States)](https://scholariq.org/institutions/pfizer-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.